Navigation Links
Pfizer Says Nigeria Gave Approval for 1996 Drug Test

US drug giant Pfizer Thursday said it had got the go-ahead from Nigerian authorities before administering a drug that claimed the lives of 11 children in the northern Kano state in 1996.

"We have written approvals from NAFDAC (Nigeria's drug agency), the federal ministry of health, Kano government and parents or guardians of the children before the clinical test of the drug was carried out," managing director of Pfizer Specialities Limited Nigeria Ngozi Edozien told reporters.

The Nigerian federal government and Kano state government have filed two separate suits against Pfizer, claiming around some 9.5 billion dollars in damages for victims of the failed drug test.

Both governments accuse Pfizer of administering a test antibiotic called Trovan without authorisation or parental consent among children at a field hospital during an epidemic of meningitis, measles and cholera.

Of the 200 children affected, 11 died while many more -- reportedly 181 -- suffered from deafness, paralysis, brain damage and blindness, according to the allegations. Pfizer denies the charges.

Edozien said Pfizer carried out the test following "an appeal for help" from Nigeria.

She said Trovan as an oral application was the best drug to treat those disease and underlined that Pfizer meant no harm.

The US Food and Drug Administration cleared Trovan for adult use in 1997 and the drug swiftly became established as one of the most prescribed antibiotics in the US market.

She said the company would defend itself against the suits during the next hearing.

The Nigerian federal government filed its suit on June 4 in Abuja for almost seven billion dollars in damages against the US drug firm, while Kano is asking for 2.5 billion dollars.

The federal suit comes up on July 20 while that of Kano government has been fixed for October 3.


'"/>




Page: 1

Related medicine news :

1. Pfizer unveils anti-smoking drug
2. The Effectiveness Of The Breast Cancer Drug By Pfizer
3. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
4. Erectile Dysfunction Drug Viagra Launched In India By Pfizer
5. Pfizer’s Eraxis Approved By The FD
6. Pfizer Launches Viagra For Lung Disease In UK
7. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
8. Pfizer Commences Its Advertising for Celebrex with All the Warnings
9. FDA Approves Pfizer’s Anti-smoking Dru
10. Pfizer vouches safety of long-term inhaled insulin.
11. NICE Setback Rules for Pfizers Inhaled Insulin
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO Jay Southerland ... version at the International Roofing Expo in Orlando, Florida on February 17-19. , ... advanced weather technology in the hands of consumers, roofing contractors, manufacturers and distributors,” ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City ... interpreting (VRI). , For nearly 23 years, Heart City Health Center has provided ...
(Date:2/10/2016)... Huntington, NY (PRWEB) , ... February 10, 2016 ... ... web-based compliance tracking solution, The Guard, to associations of medical professionals throughout the ... HIPAA compliance, including security risk assessments, policies and procedures, employee training, regulatory updates, ...
(Date:2/10/2016)... ... ... Emergency rooms provide emergency care to stabilize critical health issues, but emergency dental ... at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, dentist ... include:, , Avulsed or knocked-out teeth , Dislodged ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... VIEW, Calif. , Feb. 10, 2016 ... of a synergistic confluence of various technologies ... value propositions, previously unavailable. These opportunities create ... and convergence, in turn, drives the development ... entrepreneurial scenario is characterized by technology convergences, ...
(Date:2/10/2016)... , Feb. 10, 2016 Mast Therapeutics, ... novel, clinical-stage therapies for sickle cell disease and heart ... offering of 29,090,910 units at a price to the ... one share of the Company,s common stock and one ... stock at an exercise price of $0.42 per share. ...
(Date:2/10/2016)... 10, 2016 /PRNewswire/ - The President of New Venture ... release of an anti-radiation product from their Research ... in the treatment of cancer using radiation and ... assist in the healing of radiation burns, even ... protect only the healthy cells from radiation damage. ...
Breaking Medicine Technology: